Biocartis Release: Notice Of Results For The Six Months Ended 30 June 2015
Mechelen, Belgium, 2 September 2015 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company, today announces that it will report its results for the six-month period ended 30 June 2015 on September 11, 2015 at 7am CEST.
Biocartis will host a conference call and a live webcast presentation at 14:00 CEST on the day of the results. The conference call and webcast will be conducted in English and can be accessed on the investor page of Biocartis’ website at: https://investors.biocartis.com/.
If you would like to participate in the Q&A, please dial in using the dial-in numbers below.
Conference Call Information
Dial-ins
Belgium +32 (0) 115 001 93
US +1 646 741 2120
UK / Standard International +44 (0) 1452 541 003
The Netherlands +31 207 168 005
France +33 170 700 780
Conference ID 26035912
The webcast presentation will be available on Biocartis’ website shortly after the call.
- ENDS -
For more information, please contact:
Biocartis
Renate Degrave (Corporate Communications and Investor Relations)
+32 15 632 600
press@biocartis.com
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Chris Welsh, Hendrik Thys
+44 (0) 203 709 5701
biocartis@consilium-comms.com
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF mutations in metastatic melanoma. Its second assay, a KRAS mutation panel for colorectal cancer has been launched in June 2015. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Further information can be found at www.biocartis.com.
Help employers find you! Check out all the jobs and post your resume.
Biocartis will host a conference call and a live webcast presentation at 14:00 CEST on the day of the results. The conference call and webcast will be conducted in English and can be accessed on the investor page of Biocartis’ website at: https://investors.biocartis.com/.
If you would like to participate in the Q&A, please dial in using the dial-in numbers below.
Conference Call Information
Dial-ins
Belgium +32 (0) 115 001 93
US +1 646 741 2120
UK / Standard International +44 (0) 1452 541 003
The Netherlands +31 207 168 005
France +33 170 700 780
Conference ID 26035912
The webcast presentation will be available on Biocartis’ website shortly after the call.
- ENDS -
For more information, please contact:
Biocartis
Renate Degrave (Corporate Communications and Investor Relations)
+32 15 632 600
press@biocartis.com
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Chris Welsh, Hendrik Thys
+44 (0) 203 709 5701
biocartis@consilium-comms.com
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF mutations in metastatic melanoma. Its second assay, a KRAS mutation panel for colorectal cancer has been launched in June 2015. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Further information can be found at www.biocartis.com.
Help employers find you! Check out all the jobs and post your resume.